BridgeBio Pharma Gross Profit 2018-2024 | BBIO

BridgeBio Pharma annual/quarterly gross profit history and growth rate from 2018 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • BridgeBio Pharma gross profit for the quarter ending September 30, 2024 was $0.002B, a 38.91% decline year-over-year.
  • BridgeBio Pharma gross profit for the twelve months ending September 30, 2024 was $0.215B, a 3006.49% increase year-over-year.
  • BridgeBio Pharma annual gross profit for 2023 was $0.007B, a 90.76% decline from 2022.
  • BridgeBio Pharma annual gross profit for 2022 was $0.074B, a 11.43% increase from 2021.
  • BridgeBio Pharma annual gross profit for 2021 was $0.067B, a 707.39% increase from 2020.
BridgeBio Pharma Annual Gross Profit
(Millions of US $)
2023 $7
2022 $74
2021 $67
2020 $8
2019 $38
2018 $
2017 $
BridgeBio Pharma Quarterly Gross Profit
(Millions of US $)
2024-09-30 $2
2024-06-30 $2
2024-03-31 $211
2023-12-31 $1
2023-09-30 $3
2023-06-30 $1
2023-03-31 $1
2022-12-31 $1
2022-09-30 $-0
2022-06-30 $73
2022-03-31 $0
2021-12-31 $11
2021-09-30 $1
2021-06-30 $54
2021-03-31 $0
2020-12-31 $0
2020-09-30 $8
2020-06-30
2020-03-31
2019-12-31 $14
2019-09-30 $24
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $5.163B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $25.287B 8.30
Dr Reddy's Laboratories (RDY) India $13.114B 25.10
Bausch Health Cos (BHC) Canada $2.795B 2.06
Supernus Pharmaceuticals (SUPN) United States $2.038B 27.75
Amphastar Pharmaceuticals (AMPH) United States $1.771B 10.65
Personalis (PSNL) United States $0.422B 0.00
Taysha Gene Therapies (TSHA) United States $0.355B 24.71
Assembly Biosciences (ASMB) United States $0.102B 0.00
Sol-Gel Technologies (SLGL) Israel $0.031B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00